% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kbel:274419,
author = {M. Köbel and E.-Y. Kang and A. Weir and P. F. Rambau and
C.-H. Lee and G. S. Nelson and P. Ghatage and N. S. Meagher
and M. J. Riggan and J. Alsop and M. S. Anglesio and M. W.
Beckmann and C. Bisinotto and M. Boisen and J. Boros and A.
H. Brand and A. Brooks-Wilson and M. E. Carney and P.
Coulson and M. Courtney-Brooks and K. L. Cushing-Haugen and
C. Cybulski and S. Deen and M. A. El-Bahrawy and E. Elishaev
and R. Erber and S. Fereday and A. Fischer and S. A. Gayther
and A. Barquin-Garcia and A. Gentry-Maharaj and C. B. Gilks
and H. Gronwald and M. Grube and P. R. Harnett and H. R.
Harris and A. D. Hartkopf and A. Hartmann and A. Hein and J.
Hendley and B. Y. Hernandez and Y. Huang and A. Jakubowska
and M. Jimenez-Linan and M. E. Jones and C. J. Kennedy and
T. Kluz and J. M. Koziak and J. Lesnock and J. Lester and J.
Lubiński and T. A. Longacre and M. Lycke and C. Mateoiu and
B. M. McCauley and V. McGuire and B. Ney and A. Olawaiye and
S. Orsulic and A. Osorio and L. Paz-Ares and T. Ramón Y
Cajal and J. H. Rothstein and M. Ruebner and M. J.
Schoemaker and M. Shah and R. Sharma and M. E. Sherman and
Y. B. Shvetsov and N. Singh and H. Steed and S. J. Storr and
A. Talhouk and N. Traficante and C. Wang and A. S.
Whittemore and M. Widschwendter and L. R. Wilkens and S. J.
Winham and J. Benitez and A. Berchuck and D. D. Bowtell and
F. J. Candido Dos Reis and I. Campbell and L. S. Cook and A.
DeFazio and J. A. Doherty and P. A. Fasching and R. T.
Fortner$^*$ and M. J. García and M. T. Goodman and E. L.
Goode and J. Gronwald and D. G. Huntsman and B. Y. Karlan
and L. E. Kelemen and S. Kommoss and N. D. Le and S. G.
Martin and U. Menon and F. Modugno and P. D. Pharoah and J.
M. Schildkraut and W. Sieh and A. Staebler and K. Sundfeldt
and A. J. Swerdlow and S. J. Ramus and J. D. Brenton},
collaboration = {A. Group},
title = {p53 and ovarian carcinoma survival: an {O}varian {T}umor
{T}issue {A}nalysis consortium study.},
journal = {The journal of pathology: clinical research},
volume = {9},
number = {3},
issn = {2056-4538},
address = {Chichester},
publisher = {Wiley},
reportid = {DKFZ-2023-00586},
pages = {208-222},
year = {2023},
note = {2023 May;9(3):208-222},
abstract = {Our objective was to test whether p53 expression status is
associated with survival for women diagnosed with the most
common ovarian carcinoma histotypes (high-grade serous
carcinoma [HGSC], endometrioid carcinoma [EC], and clear
cell carcinoma [CCC]) using a large multi-institutional
cohort from the Ovarian Tumor Tissue Analysis (OTTA)
consortium. p53 expression was assessed on 6,678 cases
represented on tissue microarrays from 25 participating OTTA
study sites using a previously validated immunohistochemical
(IHC) assay as a surrogate for the presence and functional
effect of TP53 mutations. Three abnormal expression patterns
(overexpression, complete absence, and cytoplasmic) and the
normal (wild type) pattern were recorded. Survival analyses
were performed by histotype. The frequency of abnormal p53
expression was $93.4\%$ (4,630/4,957) in HGSC compared to
$11.9\%$ (116/973) in EC and $11.5\%$ (86/748) in CCC. In
HGSC, there were no differences in overall survival across
the abnormal p53 expression patterns. However, in EC and
CCC, abnormal p53 expression was associated with an
increased risk of death for women diagnosed with EC in
multivariate analysis compared to normal p53 as the
reference (hazard ratio [HR] = 2.18, $95\%$ confidence
interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR =
1.57, $95\%$ CI 1.11-2.22, p = 0.012). Abnormal p53 was also
associated with shorter overall survival in The
International Federation of Gynecology and Obstetrics stage
I/II EC and CCC. Our study provides further evidence that
functional groups of TP53 mutations assessed by abnormal
surrogate p53 IHC patterns are not associated with survival
in HGSC. In contrast, we validate that abnormal p53 IHC is a
strong independent prognostic marker for EC and demonstrate
for the first time an independent prognostic association of
abnormal p53 IHC with overall survival in patients with
CCC.},
keywords = {TP53 (Other) / clear cell (Other) / endometrioid (Other) /
high-grade serous carcinoma (Other) / ovarian cancer (Other)
/ p53 (Other) / prognosis (Other)},
cin = {C020},
ddc = {610},
cid = {I:(DE-He78)C020-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:36948887},
doi = {10.1002/cjp2.311},
url = {https://inrepo02.dkfz.de/record/274419},
}